180 related articles for article (PubMed ID: 37445886)
1. Preclinical Assessment of ADAM9-Responsive Mesoporous Silica Nanoparticles for the Treatment of Pancreatic Cancer.
Slapak EJ; El Mandili M; Brink MST; Kros A; Bijlsma MF; Spek CA
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445886
[TBL] [Abstract][Full Text] [Related]
2. CAPN2-responsive mesoporous silica nanoparticles: A promising nanocarrier for targeted therapy of pancreatic cancer.
Slapak EJ; El Mandili M; Ten Brink MS; Kros A; Bijlsma MF; Spek CA
Cancer Lett; 2024 May; 590():216845. PubMed ID: 38589004
[TBL] [Abstract][Full Text] [Related]
3. ADAM9-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Pancreatic Cancer.
Slapak EJ; Kong L; El Mandili M; Nieuwland R; Kros A; Bijlsma MF; Spek CA
Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34282781
[TBL] [Abstract][Full Text] [Related]
4. Functionalized Mesoporous Silica Nanoparticles for Drug-Delivery to Multidrug-Resistant Cancer Cells.
Igaz N; Bélteky P; Kovács D; Papp C; Rónavári A; Szabó D; Gácser A; Kónya Z; Kiricsi M
Int J Nanomedicine; 2022; 17():3079-3096. PubMed ID: 35859731
[TBL] [Abstract][Full Text] [Related]
5. Polyaspartic acid-anchored mesoporous silica nanoparticles for pH-responsive doxorubicin release.
Hakeem A; Zahid F; Zhan G; Yi P; Yang H; Gan L; Yang X
Int J Nanomedicine; 2018; 13():1029-1040. PubMed ID: 29497295
[TBL] [Abstract][Full Text] [Related]
6. Chitosan-capped mesoporous silica nanoparticles as pH-responsive nanocarriers for controlled drug release.
Hu X; Wang Y; Peng B
Chem Asian J; 2014 Jan; 9(1):319-27. PubMed ID: 24115568
[TBL] [Abstract][Full Text] [Related]
7. Mesoporous Silica Nanoparticle-Based Drug Delivery Systems for the Treatment of Pancreatic Cancer: A Systematic Literature Overview.
Slapak EJ; El Mandili M; Bijlsma MF; Spek CA
Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214121
[TBL] [Abstract][Full Text] [Related]
8. Folic acid modified lipid-bilayer coated mesoporous silica nanoparticles co-loading paclitaxel and tanshinone IIA for the treatment of acute promyelocytic leukemia.
Li Z; Zhang Y; Zhu C; Guo T; Xia Q; Hou X; Liu W; Feng N
Int J Pharm; 2020 Aug; 586():119576. PubMed ID: 32603839
[TBL] [Abstract][Full Text] [Related]
9. Lectin-conjugated pH-responsive mesoporous silica nanoparticles for targeted bone cancer treatment.
Martínez-Carmona M; Lozano D; Colilla M; Vallet-Regí M
Acta Biomater; 2018 Jan; 65():393-404. PubMed ID: 29127069
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe
Fang Z; Li X; Xu Z; Du F; Wang W; Shi R; Gao D
Int J Nanomedicine; 2019; 14():5785-5797. PubMed ID: 31440047
[No Abstract] [Full Text] [Related]
11. Aptamer Tethered Bio-Responsive Mesoporous Silica Nanoparticles for Efficient Targeted Delivery of Paclitaxel to Treat Ovarian Cancer Cells.
Salve R; Kumar P; Chaudhari BP; Gajbhiye V
J Pharm Sci; 2023 May; 112(5):1450-1459. PubMed ID: 36669561
[TBL] [Abstract][Full Text] [Related]
12. Design and characterization of dual responsive mesoporous silica nanoparticles for breast cancer targeted therapy.
Bhavsar DB; Patel V; Sawant KK
Eur J Pharm Sci; 2020 Sep; 152():105428. PubMed ID: 32553643
[TBL] [Abstract][Full Text] [Related]
13. Enzyme-induced and tumor-targeted drug delivery system based on multifunctional mesoporous silica nanoparticles.
Cheng YJ; Luo GF; Zhu JY; Xu XD; Zeng X; Cheng DB; Li YM; Wu Y; Zhang XZ; Zhuo RX; He F
ACS Appl Mater Interfaces; 2015 May; 7(17):9078-87. PubMed ID: 25893819
[TBL] [Abstract][Full Text] [Related]
14. Thermo-responsive mesoporous silica/lipid bilayer hybrid nanoparticles for doxorubicin on-demand delivery and reduced premature release.
Zhang Q; Chen X; Shi H; Dong G; Zhou M; Wang T; Xin H
Colloids Surf B Biointerfaces; 2017 Dec; 160():527-534. PubMed ID: 29024917
[TBL] [Abstract][Full Text] [Related]
15. Improving paclitaxel pharmacokinetics by using tumor-specific mesoporous silica nanoparticles with intraperitoneal delivery.
Fu Q; Hargrove D; Lu X
Nanomedicine; 2016 Oct; 12(7):1951-1959. PubMed ID: 27151564
[TBL] [Abstract][Full Text] [Related]
16. Preparation of MSNs@Keratin as pH/GSH dual responsive drug delivery system.
Shang Y; Du J; Wang B; Lu P; Zhao Y; Yuan J
J Biomater Sci Polym Ed; 2022 Aug; 33(11):1369-1382. PubMed ID: 35319342
[TBL] [Abstract][Full Text] [Related]
17. Polydopamine and peptide decorated doxorubicin-loaded mesoporous silica nanoparticles as a targeted drug delivery system for bladder cancer therapy.
Wei Y; Gao L; Wang L; Shi L; Wei E; Zhou B; Zhou L; Ge B
Drug Deliv; 2017 Nov; 24(1):681-691. PubMed ID: 28414557
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticle combination for precise stroma modulation and improved delivery for pancreatic cancer.
Tarannum M; Holtzman K; Dréau D; Mukherjee P; Vivero-Escoto JL
J Control Release; 2022 Jul; 347():425-434. PubMed ID: 35569588
[TBL] [Abstract][Full Text] [Related]
19. Egg-yolk core-shell mesoporous silica nanoparticles for high doxorubicin loading and delivery to prostate cancer cells.
Tiburcius S; Krishnan K; Jose L; Patel V; Ghosh A; Sathish CI; Weidenhofer J; Yang JH; Verrills NM; Karakoti A; Vinu A
Nanoscale; 2022 May; 14(18):6830-6845. PubMed ID: 35441642
[TBL] [Abstract][Full Text] [Related]
20. Meta-Analysis of Efficacy of Chemotherapy Delivered by Mesoporous Silica Nanoparticles to Tumor-Bearing Mice.
McGoron A
Crit Rev Biomed Eng; 2020; 48(6):327-418. PubMed ID: 33641279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]